哈藥股份(600664.SH):國家藥品監督管理局本次註銷為顛茄磺苄啶片藥品註冊證書,並非“瀉利停”商標
格隆匯1月10日丨哈藥股份(600664.SH)公佈澄清公吿,關注到部分媒體出現“瀉立停被‘喊停’”、“‘瀉立停’被全面禁售”等報道,相關信息引起投資者的關注並造成一定程度的誤導,現予以澄清説明。近日,國家藥品監督管理局官網發佈了關於註銷顛茄磺苄啶片藥品註冊證書的公吿,停止顛茄磺苄啶片在我國的生產、銷售、使用,註銷藥品註冊證書。有媒體報道稱,“顛茄磺苄啶片,就是大眾所熟知的‘瀉立停’”。
1、公司分公司哈藥集團製藥六廠(簡稱“哈藥六廠”)歷史上曾有“顛茄磺苄啶片”註冊批件,但該產品已於2018年停產,2020年公司主動未申請再註冊,該批文已廢止。國家藥品監督管理局發佈的《國家藥監局關於註銷顛茄磺苄啶片藥品註冊證書的公吿》(2025年第2號),其附件品種信息表中所列的80個被註銷的顛茄磺苄啶片批准文號中沒有公司產品。
2、公司擁有“瀉利停”商標,該商標是經國家知識產權局註冊批准使用的商標。國家藥品監督管理局本次註銷為顛茄磺苄啶片藥品註冊證書,並非“瀉利停”商標。目前“瀉利停”商標正常使用,冠有該商標的產品正常銷售,該商標項下沒有顛茄磺苄啶片產品。網上報道將商標名稱與藥品名稱混淆,對廣大投資者造成一定誤導。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.